| Literature DB >> 35098570 |
Zahra Firoozi1, Elham Mohammadisoleimani2, Abbas Shahi3,4, Hosein Mansoori1, Mohammad Mehdi Naghizadeh4, Milad Bastami4, Ziba Nariman-Saleh-Fam5, Abdolreza Daraei6, Atefeh Raoofat7, Yaser Mansoori1,4.
Abstract
BACKGROUND: Breast cancer (BC) is one of the leading causes of death among women around the world. Circular RNAs (circRNAs) are a newly discovered group of non-coding RNAs that their roles are being investigated in BC and other cancer types. In this study, we evaluated the association of hsa_circ_0005986 and hsa_circ_000839 in tumor and adjacent normal tissues of BC patients with their clinicopathological characteristics.Entities:
Keywords: breast cancer; circRNAs; hsa_circ_0005986; hsa_circ_000839
Mesh:
Substances:
Year: 2022 PMID: 35098570 PMCID: PMC8906031 DOI: 10.1002/jcla.24263
Source DB: PubMed Journal: J Clin Lab Anal ISSN: 0887-8013 Impact factor: 2.352
Relation of hsa_circ_0005986 and hsa_circ_000839 expression with clinicopathological and demographic characteristics in breast cancer patients
| hsa_circ_0005986 level | hsa_circ_000839 level | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Mean | SD | Median |
| N | Mean | SD | Median |
| ||
| Age | <50 | 22 | 1.074 | 3.405 | 0.179 | 0.452 | 22 | 1.146 | 1.621 | 0.738 | 0.754 |
| ≥50 | 28 | 0.416 | 0.700 | 0.243 | 28 | 1.324 | 1.805 | 0.621 | |||
| Tumor size | <2.5 cm | 31 | 0.373 | 0.678 | 0.191 | 0.294 | 31 | 1.322 | 1.712 | 0.794 | 0.294 |
| ≥2.5 cm | 19 | 1.247 | 3.646 | 0.262 | 19 | 1.121 | 1.749 | 0.438 | |||
| Estrogen receptor | Negative | 1 | 0.778 | 0 | 0.778 | 0.136 | 1 | 2.383 | 0 | 2.383 | 0.177 |
| Positive | 49 | 0.704 | 2.337 | 0.213 | 49 | 1.222 | 1.721 | 0.654 | |||
| Progesterone receptor | Negative | 2 | 1.923 | 2.663 | 1.923 | 0.882 | 2 | 1.143 | .867 | 1.143 | 0.621 |
| Positive | 48 | .655 | 2.315 | 0.220 | 48 | 1.250 | 1.743 | 0.695 | |||
| HER2 | Negative | 33 | .947 | 2.826 | 0.251 | 0.223 | 33 | 1.303 | 1.968 | 0.736 | 0.838 |
| Positive | 17 | 0.235 | 0.222 | 0.139 | 17 | 1.135 | 1.096 | 0.587 | |||
| Nuclear grade | 1 | 6 | 0.228 | 0.201 | 0.171 | 0.743 | 6 | .845 | 0.721 | 0.592 | 0.953 |
| 2 | 36 | 0.462 | 0.781 | 0.243 | 36 | 1.381 | 1.956 | 0.648 | |||
| 3 | 8 | 2.158 | 5.608 | 0.187 | 8 | .935 | 0.807 | 0.738 | |||
| Lymph node metastasis | Yes | 15 | 1.471 | 4.104 | 0.161 | 0.907 | 15 | 1.145 | 1.972 | 0.394 | 0.144 |
| No | 35 | 0.377 | 0.636 | 0.227 | 35 | 1.288 | 1.617 | 0.825 | |||
| Age at FFTP | <25 | 31 | 0.907 | 2.885 | 0.251 | 0.382 | 31 | 1.333 | 1.735 | 0.654 | 0.634 |
| ≥25 | 13 | 0.254 | 0.257 | 0.139 | 13 | 0.843 | 0.647 | 0.741 | |||
| Age at menarche | <14 | 31 | 0.818 | 2.879 | 0.145 | 0.108 | 31 | 1.303 | 2.078 | 0.467 | 0.255 |
| ≥14 | 19 | 0.521 | 0.830 | 0.251 | 19 | 1.151 | 0.871 | 0.974 | |||
| Age at menopause | <50 | 14 | 0.250 | 0.242 | 0.186 | 0.266 | 14 | 0.914 | 0.642 | 0.900 | 0.637 |
| ≥50 | 21 | 0.477 | 0.791 | 0.262 | 21 | 1.538 | 2.033 | 0.654 | |||
| Number of abortions | 0 | 36 | 0.869 | 2.715 | 0.202 | 0.430 | 36 | 1.274 | 1.942 | 0.641 | 0.136 |
| 1 | 12 | 0.317 | 0.230 | 0.243 | 12 | 1.321 | 0.931 | 1.102 | |||
| >1 | 2 | 0.097 | 0.056 | 0.097 | 2 | 0.268 | 0.019 | 0.268 | |||
| Hair dye use | No | 10 | 1.992 | 4.940 | 0.437 | 0.012 | 10 | 1.193 | 0.854 | 1.061 | 0.344 |
| Yes | 40 | 0.384 | 0.747 | 0.142 | 40 | 1.259 | 1.874 | 0.641 | |||
Abbreviations: FFTP, first full‐term pregnancy; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.
Relation of hsa_circ_0005986 and hsa_circ_000839 expression with clinicopathological characteristics in breast cancer patients, according to dividing patients into two groups of high and low expressions
| hsa_circ_0005986 level | hsa_circ_000839 level | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Low | High |
| Low | High |
| ||||||
| N | % | N | % | N | % | N | % | ||||
| Age | <50 | 12 | 54.5% | 10 | 45.5% | 0.569 | 10 | 45.5% | 12 | 54.5% | 0.569 |
| ≥50 | 13 | 46.4% | 15 | 53.6% | 15 | 53.6% | 13 | 46.4% | |||
| Menopausal status | Pre | 9 | 60.0% | 6 | 40.0% | 0.355 | 19 | 61.3% | 12 | 38.7% | 0.355 |
| Post | 16 | 45.7% | 19 | 54.3% | 6 | 31.6% | 13 | 68.4% | |||
| Age at menopause | <50 | 7 | 50.0% | 7 | 50.0% | 0.679 | 9 | 60.0% | 6 | 40.0% | 0.332 |
| ≥50 | 9 | 42.9% | 12 | 57.1% | 16 | 45.7% | 19 | 54.3% | |||
| BMI | ≤25 | 9 | 45.0% | 11 | 55.0% | 0.826 | 5 | 35.7% | 9 | 64.3% | 0.047 |
| 25–29 | 12 | 54.5% | 10 | 45.5% | 11 | 52.4% | 10 | 47.6% | |||
| ≥30 | 4 | 50.0% | 4 | 50.0% | 6 | 30.0% | 14 | 70.0% | |||
| Age at FFTP | <25 | 13 | 41.9% | 18 | 58.1% | 0.099 | 15 | 68.2% | 7 | 31.8% | 0.741 |
| ≥25 | 9 | 69.2% | 4 | 30.8% | 4 | 50.0% | 4 | 50.0% | |||
| Breastfeeding duration | 0 | 3 | 50.0% | 3 | 50.0% | 0.811 | 16 | 51.6% | 15 | 48.4% | 0.811 |
| <24 | 8 | 57.1% | 6 | 42.9% | 6 | 46.2% | 7 | 53.8% | |||
| ≥24 | 14 | 46.7% | 16 | 53.3% | 3 | 50.0% | 3 | 50.0% | |||
| Abortion history | No | 19 | 52.8% | 17 | 47.2% | 0.529 | 6 | 42.9% | 8 | 57.1% | 0.208 |
| Yes | 6 | 42.9% | 8 | 57.1% | 16 | 53.3% | 14 | 46.7% | |||
| Tumor size | <2.5 cm | 17 | 54.8% | 14 | 45.2% | 0.382 | 20 | 55.6% | 16 | 44.4% | 0.382 |
| ≥2.5 cm | 8 | 42.1% | 11 | 57.9% | 5 | 35.7% | 9 | 64.3% | |||
| Estrogen receptor | Negative | 0 | 0.0% | 1 | 100.0% | 0.312 | 14 | 45.2% | 17 | 54.8% | 0.312 |
| Positive | 25 | 51.0% | 24 | 49.0% | 11 | 57.9% | 8 | 42.1% | |||
| Progesterone receptor | Negative | 1 | 50.0% | 1 | 50.0% | 1.000 | 0 | 0.0% | 1 | 100.0% | 1.000 |
| Positive | 24 | 50.0% | 24 | 50.0% | 25 | 51.0% | 24 | 49.0% | |||
| Her2 | Negative | 15 | 45.5% | 18 | 54.5% | 0.370 | 1 | 50.0% | 1 | 50.0% | 0.765 |
| Positive | 10 | 58.8% | 7 | 41.2% | 24 | 50.0% | 24 | 50.0% | |||
Abbreviations: BMI, body mass index; FFTP, first full‐term pregnancy.
Primers sequences
| CircRNAs and housekeeping gene | Primer | |
|---|---|---|
| hsa_circ_0005986 | Forward | CTATAAAACTTTAAAGAACACTACTGAGCC |
| Reverse | GGGTCTTGTCAACAGCAGAA | |
| hsa_circ_000839 | Forward | CAATCTTGTAGTTATACATTGGC |
| Reverse | AGTCTAAAGCACAGGGAAC | |
| B2 M (housekeeping gene) | Forward | AGATGAGTATGCCTGCCGTG |
| Reverse | GCGGCATCTTCAAACCTCCA | |
FIGURE 1Box and whisker plot (Tukey style, outliers in black dots) of the expression of hsa_circ_0005986 and hsa_circ_000839 in tumors and paired non‐cancerous tissues. (A, B) Down expression of both hsa_circ_0005986 and hsa_circ_000839 in tumors compared with adjacent normal tissues (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001)
FIGURE 2Box and whisker plot (Tukey style, outliers in black dots) of the expression level of hsa_circ_0005986 and hsa_circ_000839 in hair dye users in the last 5 years (n = 40) and non‐users in this time period (n = 10) (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001)
FIGURE 3Correlation between BMI and expression levels of hsa_circ_000839 (r = −0.357, p‐value = 0.01)
FIGURE 4The triple regulatory networks of circRNA‐miRNA‐mRNA were constructed based on circRNA‐miRNA pairs, miRNA‐mRNA pairs, and PPI. Pink indicates circRNAs, jade indicates miRNAs, and purple indicates mRNAs. The yellow mRNAs play the role as a transcription factor. In order to evaluate the genes with transcription factor role, we used TF2DNA (http://fiserlab.org/tf2dna_db//search_genes.html) database. A and B are ceRNA network hsa_circ_000839 and hsa_circ_0005986, respectively
Expression of miRNAs involved in hsa_circ_000839 network in TCGA‐BRCA
| TCGA‐Breast Cancer | Fold change | Log2 (fold change) | Mean RPM (Tumor) | Mean RPM (Normal) |
| Adjusted |
|---|---|---|---|---|---|---|
| Hsa‐mir−654‐3p | −2.11 | −1.08 | 21.02 | 44.44 | 2.73e−27 | 1.36e−26 |
| Hsa‐mir−331‐3p | 1.99 | 1 | 33.08 | 16.59 | 1.45e−16 | 4.14e−16 |
| Hsa‐mir−409‐3p | −1.22 | −0.28 | 14.37 | 17.48 | 0.0308 | 0.0383 |
| Hsa‐mir−590‐5p | 2.07 | 1.05 | 14.23 | 6.87 | 6.18e−21 | 2.14e−20 |
| Hsa‐mir−944 | −2.95 | −1.56 | 1.9 | 5.63 | 1.9e−18 | 5.91e−18 |
Expression of mRNAs involved in hsa_circ_000839 network in TCGA‐BRCA
| TCGA‐Breast Cancer | Fold change | Log2 (fold change) | Mean RPM (Tumor) | Mean RPM (Normal) |
| Adjusted |
|---|---|---|---|---|---|---|
| E2F1 | 6.69 | 2.74 | 481.58 | 72.02 | 7.25e−55 | 2.49e−53 |
| DOHH | 1.92 | 0.94 | 249.61 | 130.1 | 2.23e−18 | 6.34e−18 |
| PHLPP1 | −1.53 | −0.61 | 529.71 | 810.35 | 4.01e−29 | 1.92e−28 |
| NACC1 | 2.68 | 1.42 | 2245.15 | 837.78 | 4.47e−60 | 4.58e−58 |
| STAG2 | −1.28 | −0.35 | 2660.04 | 3396.02 | 4.19e−18 | 1.18e−17 |
| RSU1 | −1.19 | −0.25 | 1704.75 | 2031.11 | 7.37e−14 | 1.69e−13 |
| NLK | 1.59 | 0.67 | 620.47 | 389.92 | 3.24e−20 | 1,00E−19 |
| AKT1 | 1.56 | 0.64 | 4685.47 | 3005.53 | 1.9e−24 | 7.21e−24 |
| ELF2 | −1.22 | −0.28 | 823.11 | 1000.64 | 1.79e−17 | 4.88e−17 |
| CDKN1A | −1.37 | −0.45 | 2089.83 | 2859.49 | 0.00108 | 0.00146 |
| TGFBR2 | −4.77 | −2.25 | 2180.65 | 10397.43 | 3.02e−61 | 4.74e−59 |
| CREB5 | −4.43 | −2.15 | 120.84 | 535.15 | 3.37e−55 | 1.21e−53 |
| SMAD3 | −1.38 | −0.46 | 1253.11 | 1729.32 | 3.32e−22 | 1.13e−21 |
| TGFB1 | 1.79 | 0.84 | 1126.35 | 627.71 | 6.16e−22 | 2.07e−21 |
| ILF3 | 1.34 | 0.42 | 5725.06 | 4284.99 | 3.19e−26 | 1.31e−25 |
| SMAD7 | −1.08 | −0.11 | 701.9 | 756.21 | 0.0167 | 0.0207 |
| EXOG | −1.15 | −0.2 | 112.16 | 129.2 | 2.25e−9 | 4.16e−9 |
| HECW2 | −1.14 | −0.19 | 243.81 | 278.16 | 0.00733 | 0.00932 |
| ERBB2 | 3.77 | 1.91 | 18327.05 | 4862.24 | 1.09e−15 | 2.72e−15 |
| HOTAIR | 6.81 | 2.77 | 131.75 | 19.36 | 9.82e−17 | 2.58e−16 |
| NACC1 | 2.68 | 1.42 | 2245.15 | 837.78 | 4.47e−60 | 4.58e−58 |
| ING5 | −1.23 | −0.3 | 400.95 | 493.68 | 4.19e−12 | 8.86e−12 |
| FGB | 6.8 | 2.77 | 318.5 | 46.8 | 0.0000614 | 0.0000897 |
| FGG | 9.43 | 3.24 | 252.52 | 26.78 | 5.27e−7 | 8.67e−7 |
| PHF10 | −1.55 | −0.64 | 1347.96 | 2094.1 | 1.92e−37 | 1.48e−36 |
| FRAT1 | 1.2 | 0.26 | 150.2 | 125.43 | 0.0112 | 0.0141 |
| RASGRP3 | −1.23 | −0.3 | 284.3 | 349.7 | 5.14e−10 | 9.82e−10 |
| NLK | 1.59 | 0.67 | 620.47 | 389.92 | 3.24e−20 | 1,00E−19 |
| AKT1 | 1.56 | 0.64 | 4685.47 | 3005.53 | 1.9e−24 | 7.21e−24 |
| ZEB1 | −2.18 | −1.13 | 721.94 | 1575.72 | 7.33e−21 | 2.35e−20 |
| GAB1 | −1.4 | −0.49 | 806.3 | 1132.79 | 1.82e−20 | 5.72e−20 |
| ATF3 | −4.31 | −2.11 | 908.78 | 3914.2 | 3.87e−39 | 3.3e−38 |
| OLR1 | 4.53 | 2.18 | 396.82 | 87.51 | 2.36e−42 | 2.48e−41 |
| RB1 | −1.2 | −0.26 | 1146.87 | 1373.79 | 6.41e−8 | 1.1e−7 |
| BTG2 | −1.56 | −0.64 | 5579.14 | 8695.09 | 1.6e−13 | 3.62e−13 |
| SIAH1 | −1.06 | −0.09 | 589.32 | 627.36 | 3.65e−7 | 6.06e−7 |
| CTNND1 | −1.05 | −0.07 | 8594.33 | 9050.41 | 0.0000029 | 0.0000046 |
| RDX | −1.56 | −0.64 | 1278.52 | 1998.39 | 1.06e−20 | 3.35e−20 |
| MET | −2.96 | −1.57 | 633.16 | 1876.17 | 2.49e−51 | 5.59e−50 |
| ANG | −1.55 | −0.63 | 328.72 | 510.24 | 5.09e−19 | 1.49e−18 |
| NRP2 | −1.15 | −0.21 | 1054.3 | 1215.51 | 0.0000667 | 0.0000972 |
| CTNND1 | −1.05 | −0.07 | 8594.33 | 9050.41 | 0.0000029 | 0.0000046 |
| CHL1 | −8.74 | −3.13 | 167.04 | 1459.62 | 4.3e−61 | 6.28e−59 |
| RECK | −3.58 | −1.84 | 307.88 | 1102.33 | 4.14e−52 | 1.01e−50 |
FIGURE 5The Most significant correlation between mRNAs and miRNAs in the hsa_circ_000839 network
FIGURE 6Data extracted from Enrichr for GO terms of genes with the highest significant correlation to miRNAs of hsa_circ_000839 network
Expression of miRNAs involved in hsa_circ_0005986 in TCGA‐BRCA
| TCGA‐Breast Cancer | Fold change | Log2 (fold change) | Mean RPM (Tumor) | Mean RPM (Normal) |
| Adjusted |
|---|---|---|---|---|---|---|
| Hsa‐mir−421 | 1.76 | 0.82 | 2.11 | 1.19 | 1.63e−8 | 3.05e−8 |
| Hsa‐mir−326 | −2.48 | −1.31 | 9.96 | 24.71 | 3.09e−27 | 1.49e−26 |
| Hsa‐mir−188‐3p | 2.1 | 1.07 | 1.16 | 0.55 | 3.04e−7 | 5.29e−7 |
Expression of mRNAs involved in hsa_circ_0005986 in TCGA‐BRCA
| TCGA‐Breast Cancer | Fold change | Log2 (fold change) | Mean RPM (Tumor) | Mean RPM (Normal) |
| Adjusted |
|---|---|---|---|---|---|---|
| SIRT3 | −1.02 | −0.02 | 763.24 | 775.43 | 0.0122 | 0.0153 |
| CBX7 | −3.04 | −1.6 | 690.29 | 2099.51 | 3.12e−58 | 1.86e−56 |
| RBMXL1 | −1.46 | −0.54 | 580.06 | 845.87 | 4.56e−34 | 2.83e−33 |
| XRCC5 | 1.18 | 0.24 | 8153.2 | 6881.78 | 3.62e−12 | 7.68e−12 |
| SMO | 1.1 | 0.14 | 554.54 | 504.59 | 0.00151 | 0.00201 |
| PKM | 1.85 | 0.89 | 22562.44 | 12187.92 | 5.1e−41 | 4.91e−40 |
| EEF1A2 | 2.58 | 1.37 | 2173.55 | 841.37 | 9.06e−21 | 2.89e−20 |
| CASP3 | 1.6 | 0.68 | 862.2 | 538.15 | 1.27e−39 | 1.11e−38 |
| NOB1 | −1.36 | −0.44 | 886.26 | 1206.14 | 2.72e−21 | 8.88e−21 |
| SP1 | −1.23 | −0.3 | 3199.05 | 3925.36 | 6.84e−18 | 1.9e−17 |
| CDH1 | 1.46 | 0.55 | 10971.64 | 7496.56 | 0.000409 | 1.46 |
| CBL | −1.47 | −0.55 | 839.15 | 1230.84 | 1.35e−24 | 5.16e−24 |
| FGF1 | −4.44 | −2.15 | 278.02 | 1233.99 | 1.96e−59 | 1.54e−57 |
| NOTCH1 | −1.35 | −0.43 | 1200.8 | 1621.72 | 3.36e−19 | 9.93e−19 |
| CD274 | 1.17 | 0.23 | 33.03 | 28.22 | 0.00541 | 0.00695 |
| BCL2L1 | 1.41 | 0.49 | 2755.09 | 1958.27 | 3.05e−22 | 1.04e−21 |
| TERT | 9.04 | 3.18 | 7.5 | 0.83 | 5.97e−23 | 2.1e−22 |
| CCND2 | −2.12 | −1.08 | 779.73 | 1649.3 | 1.91e−47 | 2.95e−46 |
| GLI1 | −1.64 | −0.71 | 28.21 | 46.3 | 2.16e−16 | 5.58e−16 |
| NOTCH2 | −1.31 | −0.39 | 5893.17 | 7713.57 | 6.23e−14 | 1.43e−13 |
| SMAD4 | −1.48 | −0.57 | 1503.76 | 2226.52 | 6.82e−39 | 5.75e−38 |
| FOXO4 | −2.04 | −1.03 | 493.83 | 1006.57 | 9,00E−49 | 1.59e−47 |
| IRS1 | −1.66 | −0.73 | 1391.9 | 2304.28 | 1.06e−24 | 4.06e−24 |
| IGF2 | −1.45 | −0.54 | 4130.7 | 5989.32 | 3.79e−36 | 2.67e−35 |
| HOTAIR | 6.81 | 2.77 | 131.75 | 19.36 | 9.82e−17 | 2.58e−16 |
| CD9 | 1.89 | 0.92 | 8784.09 | 4650.33 | 9.16e−32 | 5.06e−31 |
| MSH3 | −1.19 | −0.26 | 512.25 | 612.13 | 1.94e−8 | 3.43e−8 |
| ATM | −1.55 | −0.63 | 997.22 | 1542.7 | 2.22e−23 | 8.01e−23 |
| GSTP1 | −1.15 | −0.21 | 3603.87 | 4157.3 | 7.78e−13 | 1.7e−12 |
FIGURE 7Association of IFNG and IGF1R expression with patient's survival using TCGA dataset in BRCA. High expression of two genes was associated with higher survival. (A) Log‐rank p related to IFNG was 0.0011. (B) Log‐rank p related to IGF1R was 0.047